Genetika+ Wins Prestigious European Funding To Bring Depression Drug Matching Platform To Market
Round Type
Funding Round
Tel AvivBiotechnologyHealth CareMedicalTherapeuticsDescription
Genetika+, a company developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases, announced today an award of up to €17.5 million of grant funding combined with equity investment to bring NeuroKaire to market. This represents the maximum possible grant from the European Commission and will be used for the company’s precision medicine tool for optimizing drug choice to treat major depressive disorder (MDD). The award was granted through the European Commission’s European Innovation Council (EIC) Accelerator for Europe’s high potential start-ups. Genetika+’s proposal was selected from over 1000 start-ups and SMEs.
Quick answer
Genetika+ raised an undisclosed amount in a Funding Round round, dated July 26, 2022. Genetika+ is based in Tel Aviv, Tel Aviv District, Israel.
- How much did Genetika+ raise?
- Genetika+ raised an undisclosed amount in a Funding Round round on July 26, 2022.
- What does Genetika+ do?
- Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases.
- Where is Genetika+ based and how big is it?
- Genetika+ is based in Tel Aviv, Tel Aviv District, Israel.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Genetika+ that raised within 45 days of this round, from Fundz verified event records.
- Abivax raised $49M (Funding Round) on September 2, 2022.
- Differentiated Therapeutics raised $5M (Seed) on August 1, 2022.
- Elevation Oncology raised $50M (Debt Financing) on July 28, 2022.
- Renibus Therapeutics raised $15M on July 15, 2022.
- Faeth Therapeutics raised $47M (Funding Round) on June 30, 2022.
- Photys Therapeutics raised $75M (Series A) on September 8, 2022.
Who to call at Genetika+, and when
A new round usually means Genetika+ is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Genetika+ raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Genetika+, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Genetika+. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Genetika+ raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Genetika+ raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.